Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High molecular weight cytokeratin antibody (clone 34βE12): a sensitive marker for differentiation of high‐grade invasive urothelial carcinoma from prostate cancer

31 Jan 2003

Abstract excerpt

AIMS: There is no well-established positive immunomarker for urothelial carcinoma. We evaluated the diagnostic utility of high molecular weight cytokeratin (HMWCK) antibody clone 34betaE12 in differentiating high-grade invasive urothelial carcinoma from prostate cancer. METHODS AND RESULTS: Formalin-fixed paraffin-embedded sections from 28 cases of high-grade invasive urothelial carcinoma (20 not otherwise...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Urinary and Genital Oncology Studies
Share to Urinary Bladder and Prostate Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12558749
DOI: 10.1046/j.1365-2559.2003.01560.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

High molecular weight cytokeratin antibody (clone 34βE12): a sensitive marker for differentiation of high‐grade invasive urothelial carcinoma from prostate cancerPMID 12558749Read ↗

Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer.Semantic proximity Read ↗

[Histomolecular classification of urothelial carcinoma of the urinary bladder : From histological phenotype to genotype and back].Semantic proximity Read ↗

A multicenter review of histopathology of variants in the context of upper urinary tract urothelial carcinoma and their impact on clinical outcomesSemantic proximity Read ↗

Select updates in the pathology of kidney, testis, and penile cancer for 2026: Including FLCN-mutated (kidney) tumors, paratesticular mesothelial tumors, and TP53/HPV status in penile squamous cell carcinoma.Semantic proximity Read ↗

[Update on urothelial carcinoma histopathology].Semantic proximity Read ↗

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Semantic proximity Read ↗

The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder CancerSemantic proximity Read ↗

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.